{
    "clinical_study": {
        "@rank": "82435", 
        "arm_group": {
            "arm_group_label": "Regorafenib", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The aim of this study is to determine at which dose regorafenib is safe for children and\n      adolescents and also to investigate the pharmacokinetics (explores what the body does to the\n      drug) of regorafenib (study drug) in children and adolescents. Additional objectives of the\n      study are:\n\n        -  To assess the tolerability of regorafenib in children and adolescents\n\n        -  To assess whether there is any tumor response to regorafenib\n\n        -  To assess the palatability and acceptability of regorafenib tablets in children"
        }, 
        "brief_title": "A Phase I Dose Finding Study in Children With Solid Tumors", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pediatric Oncology", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age: from 5 years to less than 18 years old\n\n          -  Pediatric subjects who are able to swallow tablets\n\n          -  Diagnosis: subjects must have had histologic verification of solid malignancy at\n             original diagnosis. Subjects with recurrent or refractory solid tumors are eligible,\n             including primary CNS tumors or subjects with known CNS metastases\n\n          -  Subject's current disease state must be one for which there is no known effective\n             therapy or therapy proven to prolong survival with an acceptable quality of life.\n             Effective therapy may include surgery, radiation therapy, chemotherapy or any\n             combination of these modalities.\n\n          -  Subjects must have at least one measurable or evaluable lesion according to Response\n             Evaluation Criteria in Solid Tumors (RECIST), version 1.1. For neuroblastoma subjects\n             with osteomedullary disease, the SIOPEN (International Society of Pediatric Oncology\n             Europe Neuroblastoma Group) score will be used.\n\n          -  Life expectancy of at least 12 weeks from the time of signing informed consent/assent\n\n          -  Performance level: Karnofsky \u2265 70% for subjects > 10 years of age and Lansky \u2265 70%\n             for subjects \u2264 10 years of age, except children with motor paresis due to disease.\n             Neurological deficits in subjects must have been stable for a minimum of 1 week prior\n             to first dose of study treatment.\n\n          -  Adequate renal, hepatic and hematologic function\n\n        Exclusion Criteria:\n\n          -  Prior treatment with regorafenib. Subjects permanently withdrawn from study\n             participation will not be allowed to re-enter the study.\n\n          -  Other anticancer treatment, including any investigational new drugs within 28 days or\n             5 drug half-lives (if drug half-life in subjects is known), whichever is shorter (or\n             within 6 weeks for mitomycin C), before start of study treatment\n\n          -  Subjects with uncontrolled baseline hypertension higher than Grade 1 NCI-CTCAE v.4.0\n             (recurrent or persistent [\u226524 hours] blood pressure [BP] >ULN: BP > the 95th\n             percentile for age, height, and gender measured)\n\n          -  Unresolved toxicity higher than NCI-CTCAE v. 4.0 Grade 1 attributed to any prior\n             therapy/procedure (excluding alopecia, chemotherapy-induced ototoxicity,  Grade 2\n             chemotherapy-induced neuropathy and, as per above eligibility criteria, anemia with\n             hemoglobin \u2265 8 mg/dL and ANC \u2265 1.0 x 10 9/L )."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02085148", 
            "org_study_id": "15906", 
            "secondary_id": "2013-003579-36"
        }, 
        "intervention": {
            "arm_group_label": "Regorafenib", 
            "description": "Regorafenib will be given orally once a day, across cycles of 28 days each. During each cycle regorafenib is taken for 3 weeks followed by one week off the drug.  Doses of the study drug used in this study are age-dependent and the children's dose will been adjusted based on the age and the body surface area.", 
            "intervention_name": "Regorafenib (BAY73-4506)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Pediatric cancer", 
        "lastchanged_date": "May 13, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lyon Cedex", 
                        "country": "France", 
                        "zip": "69008"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75005"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif Cedex", 
                        "country": "France", 
                        "zip": "94805"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "zip": "20133"
                    }
                }, 
                "status": "Terminated"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sutton", 
                        "country": "United Kingdom", 
                        "state": "Surrey", 
                        "zip": "SM2 5PT"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Italy", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-center, Open-label, Non-randomized, Phase I Dose Escalation Study of Regorafenib (BAY 73-4506) in Pediatric Subjects With Solid Malignant Tumors That Are Recurrent or Refractory to Standard Therapy.", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Italy: The Italian Medicines Agency", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety: Maximum Tolerated Dose", 
                "safety_issue": "Yes", 
                "time_frame": "approximately after 21 months"
            }, 
            {
                "measure": "Safety: Recommended Phase II Dose", 
                "safety_issue": "Yes", 
                "time_frame": "approximately after 21 months"
            }, 
            {
                "measure": "Safety: Individual listings of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "approximately after 21 months"
            }, 
            {
                "measure": "Pharmacokinetics: Area under the concentration curve based on nominal dosing", 
                "safety_issue": "Yes", 
                "time_frame": "approximately after 21 months"
            }, 
            {
                "measure": "Pharmacokinetics: Maximum plasma concentration", 
                "safety_issue": "Yes", 
                "time_frame": "approximately after 21 months"
            }, 
            {
                "measure": "Pharmacokinetics: Average plasma concentration", 
                "safety_issue": "Yes", 
                "time_frame": "approximately after 21 months"
            }, 
            {
                "measure": "Pharmacokinetics: Effective half-life", 
                "safety_issue": "Yes", 
                "time_frame": "approximately after 21 months"
            }, 
            {
                "measure": "Pharmacokinetics: Area under the concentration curve based on individual dosing", 
                "safety_issue": "Yes", 
                "time_frame": "approximately after 21 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02085148"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "approximately after 21 months"
            }, 
            {
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "approximately after 21 months"
            }, 
            {
                "measure": "Tumor response: tumor assessment by RECIST v. 1.1", 
                "safety_issue": "No", 
                "time_frame": "approximately after 21 months"
            }, 
            {
                "measure": "Acceptability and palatability of the formulations - tablets and granulates: Taste and texture questionnaire", 
                "safety_issue": "No", 
                "time_frame": "approximately after 21 months"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}